pharmaceuticals

Top picks for long-term care

From top holding to 1% in 12 months

2018 should be another intensive year for BB Biotech, with many important clinical trial results and regulatory approvals expected to keep the biotechnology industry and BB Biotech's holdings in focus. The investment team expects new product launches...

Key to maintaining a balanced approach

Big sustainability challenges being tackled

Over the years we have found the vast majority of our investment opportunities by focusing on stocks that have significantly underperformed.

TER of 0.35%

Political and market shocks

Improved engagement

'Unjustly punished in sell-off last year'